Genetic mutation as biomarker for advanced cancer patients receiving apatinib: An analysis based on whole exome sequencing.

e24219Background: Apatinib, a VEGFR-2 inhibitor, has shown significant anti-tumor effects in the treatment of advanced solid tumors. However no biomarkers identified to predict the benefits treated...